Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels
BRISBANE, Calif. & NEW YORK--(BUSINESS WIRE)--Jul 5, 2019--
BRISBANE, Calif. & NEW YORK--(BUSINESS WIRE)--Jul 5, 2019--